MA24930A1 - Forme posologique a usage oral comprenant une combinaison de metformine et de glibenclamide - Google Patents

Forme posologique a usage oral comprenant une combinaison de metformine et de glibenclamide

Info

Publication number
MA24930A1
MA24930A1 MA25681A MA25681A MA24930A1 MA 24930 A1 MA24930 A1 MA 24930A1 MA 25681 A MA25681 A MA 25681A MA 25681 A MA25681 A MA 25681A MA 24930 A1 MA24930 A1 MA 24930A1
Authority
MA
Morocco
Prior art keywords
glibenclamide
metformin
combination
dosage form
oral dosage
Prior art date
Application number
MA25681A
Other languages
English (en)
French (fr)
Inventor
Yves Bonhomme
Geoffrey Nicholson
Sarah J Nicholson
Gillian Cave
Original Assignee
Lipha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8235441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA24930(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lipha filed Critical Lipha
Publication of MA24930A1 publication Critical patent/MA24930A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA25681A 1998-07-15 1999-07-13 Forme posologique a usage oral comprenant une combinaison de metformine et de glibenclamide MA24930A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98401781A EP0974356B1 (en) 1998-07-15 1998-07-15 Tablets comprising a combination of metformin and glibenclamide

Publications (1)

Publication Number Publication Date
MA24930A1 true MA24930A1 (fr) 2000-04-01

Family

ID=8235441

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25681A MA24930A1 (fr) 1998-07-15 1999-07-13 Forme posologique a usage oral comprenant une combinaison de metformine et de glibenclamide

Country Status (27)

Country Link
US (2) US6303146B1 (enExample)
EP (4) EP0974356B1 (enExample)
JP (2) JP2002520371A (enExample)
KR (2) KR100478347B1 (enExample)
CN (2) CN1146427C (enExample)
AP (1) AP1450A (enExample)
AR (2) AR013052A1 (enExample)
AT (1) ATE250418T1 (enExample)
AU (2) AU753604B2 (enExample)
BR (1) BR9906600A (enExample)
CA (1) CA2303537C (enExample)
DE (1) DE69818444T2 (enExample)
DK (1) DK0974356T3 (enExample)
DZ (1) DZ2846A1 (enExample)
ES (1) ES2206868T3 (enExample)
ID (1) ID25784A (enExample)
MA (1) MA24930A1 (enExample)
MY (1) MY129552A (enExample)
NZ (1) NZ503248A (enExample)
OA (1) OA11400A (enExample)
PT (1) PT974356E (enExample)
RU (2) RU2226396C2 (enExample)
SI (1) SI0974356T1 (enExample)
TW (2) TW555560B (enExample)
UY (1) UY25611A1 (enExample)
WO (1) WO2000003742A2 (enExample)
ZA (1) ZA200001159B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
BR0015294A (pt) * 1999-11-03 2003-07-15 Bristol Myers Squibb Co Método para tratamento da diabetes
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2816841B1 (fr) * 2000-11-22 2004-02-06 Lipha Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation
US7964216B2 (en) * 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US7879869B2 (en) 2001-07-30 2011-02-01 Mitsubishi Tanabe Pharma Corporation Drugs for ameliorating postcibal hyperglycemia
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
ATE361065T1 (de) * 2002-01-25 2007-05-15 Silanes Sa De Cv Lab Pharmazeutische zusammensetzung zur kontrolle des blutzuckers bei patienten mit typ 2 diabetes
AU2003211146B2 (en) * 2002-02-21 2007-07-19 Valeant International (Barbados) Srl Controlled release dosage forms
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
ES2314227T7 (es) 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
PL376577A1 (pl) 2002-06-17 2006-01-09 Themis Laboratories Private Limited Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
US7445796B2 (en) * 2002-08-19 2008-11-04 L. Perrigo Company Pharmaceutically active particles of a monomodal particle size distribution and method
EP1562607A1 (en) * 2002-11-15 2005-08-17 Ranbaxy Laboratories, Ltd. Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
FR2853831A1 (fr) * 2003-03-05 2004-10-22 Usv Ltd Forme posologique solide a usage oral de metformine et de glyburide et son procede de preparation
EP1629851A1 (en) * 2003-04-15 2006-03-01 Chugai Seiyaku Kabushiki Kaisha Remedy for diabetes
US20060121108A1 (en) * 2004-12-02 2006-06-08 Prasad C K System and method for producing a directly compressible, high-potency formulation of metformin hydrochloride
CN100341495C (zh) * 2004-12-29 2007-10-10 三九医药股份有限公司 格列本脲固体分散体、口服组合物及其制备方法
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
UY29445A1 (es) * 2005-03-30 2006-10-02 Generex Pharm Inc Composiciones para la transmisión transmucosa oral de la metformina
US8529537B2 (en) * 2005-08-05 2013-09-10 Kimberly-Clark Worldwide, Inc. Absorbent article with enclosures
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
CA2787343C (en) 2006-06-26 2016-08-02 Amgen Inc. Compositions comprising modified lcat and uses thereof
WO2008062273A2 (en) * 2006-11-20 2008-05-29 Cadila Pharmaceuticals Limited Solid oral dosage form having antidiabetic drug combination
AR067557A1 (es) 2007-07-19 2009-10-14 Takeda Pharmaceutical Preparacion solida y metodo de preparacion
SI2489731T1 (sl) 2007-07-26 2014-12-31 Amgen Inc. Patent Operations, M/S 28-2-C Modificirani encimi lecitin-holesterol aciltransferaze
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
WO2011135106A1 (es) * 2010-04-26 2011-11-03 Smart Pharma Solutions, S.L Granulado altamente dispersable para la preparación de formulaciones de sustancias activas de altas dosis y procedimiento de obtención del mismo
RU2451506C1 (ru) 2011-06-02 2012-05-27 Сергей Юрьевич Лешков Комбинация для лечения сахарного диабета и его осложнений
WO2013086443A1 (en) 2011-12-08 2013-06-13 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
WO2013090452A1 (en) * 2011-12-12 2013-06-20 Orbis Biosciences, Inc. Sustained release particle formulations
CN104127424A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列本脲衍生物及其制备方法和应用
CN105030793A (zh) * 2015-08-25 2015-11-11 瑞阳制药有限公司 二甲双胍格列本脲胶囊及其制备方法
WO2019070109A1 (es) * 2017-10-03 2019-04-11 Infinite Clinical Research International, S.A. De C.V. Triconjugado para el tratamiento de diabetes mellitus
CN115315426B (zh) 2020-04-01 2023-12-12 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
EP4130005A4 (en) 2020-04-01 2024-04-24 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF
KR102484756B1 (ko) * 2020-11-13 2023-01-06 한국생산기술연구원 용해성 증대 및 취급용이성을 갖는 파우더 배지의 과립화 방법
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE362704C (de) * 1921-08-09 1922-11-02 Naamlooze Vennootschap Interna Vorrichtung zum Senken einer Last, insbesondere eines Rettungsbootes
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE2348334C2 (de) 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
US4916163A (en) 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
IE63463B1 (en) * 1989-02-06 1995-04-19 Zeneca Ltd Phenylsulphone derivatives
GB9016978D0 (en) * 1990-08-02 1990-09-19 Ici Plc Acetamide derivatives
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
TR199903057T2 (xx) 1997-06-18 2000-04-21 Smithkline Beecham Plc Diabetin tiazolidinedion ve metformin ile tedavisi.
US6544564B1 (en) * 2001-11-27 2003-04-08 Michael Donald Farley Cytotoxic pharmaceutical composition

Also Published As

Publication number Publication date
USRE38629E1 (en) 2004-10-19
AR065970A2 (es) 2009-07-15
EP1435240A2 (en) 2004-07-07
EP1435240A3 (en) 2009-08-12
ATE250418T1 (de) 2003-10-15
SI0974356T1 (en) 2003-12-31
TW555560B (en) 2003-10-01
EP0974356B1 (en) 2003-09-24
AP1450A (en) 2005-07-25
CA2303537C (en) 2005-12-06
AP2000001757A0 (en) 2000-03-31
KR100478347B1 (ko) 2005-03-23
ES2206868T3 (es) 2004-05-16
RU2286788C2 (ru) 2006-11-10
RU2003126257A (ru) 2005-02-27
OA11400A (en) 2004-04-08
CN1275082A (zh) 2000-11-29
JP2002520371A (ja) 2002-07-09
DE69818444D1 (de) 2003-10-30
EP0974356A1 (en) 2000-01-26
AU5417999A (en) 2000-02-07
MY129552A (en) 2007-04-30
TW200303208A (en) 2003-09-01
US6303146B1 (en) 2001-10-16
DK0974356T3 (da) 2003-10-27
EP1011684A2 (en) 2000-06-28
KR20010030603A (ko) 2001-04-16
WO2000003742A2 (en) 2000-01-27
WO2000003742A3 (en) 2000-04-20
CA2303537A1 (en) 2000-01-27
PT974356E (pt) 2004-02-27
JP2003292443A (ja) 2003-10-15
DZ2846A1 (fr) 2003-12-01
RU2226396C2 (ru) 2004-04-10
EP2269613A3 (en) 2012-10-17
EP2269613A2 (en) 2011-01-05
ID25784A (id) 2000-11-02
ZA200001159B (en) 2001-05-31
KR20040053177A (ko) 2004-06-23
AR013052A1 (es) 2000-11-22
DE69818444T2 (de) 2004-05-06
NZ503248A (en) 2002-09-27
CN1486698A (zh) 2004-04-07
UY25611A1 (es) 2000-08-21
BR9906600A (pt) 2000-07-18
CN1146427C (zh) 2004-04-21
AU2003261560A1 (en) 2005-05-26
TWI245632B (en) 2005-12-21
AU753604B2 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
DZ2846A1 (fr) Forme posologique à usage oral comprenant une combinaison de metformine et de glibenclamide.
HUP0301972A2 (hu) Fentanilszerű szerkezetű opioidot és ketamint tartalmazó hatóanyag-kombináció és ezt tartalmazó gyógyszerkészítmény
TNSN01145A1 (fr) Derives d'imidazole a noyau aryle ou heteroaryle condense, et compositions les contenant.
TNSN02009A1 (fr) Pyrimidinones bicycliques condensees nouvelles, inhibitrices de mmp, et compositions les contenant.
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
SE0001899D0 (sv) New compounds
BR0109943A (pt) Composições farmacêuticas
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
BRPI9917007B8 (pt) azabicicloalcanos como moduladores de ccr5, composição farmacêutica contendo os mesmos, bem como seu uso
BR9810495A (pt) Composição farmacêutica
IL165601A0 (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
TNSN00191A1 (fr) Composes nouveaux, compositions les contenant et leur utilisation dans le traitement d'une ischemie
TR200102836T2 (tr) Bitki zararlılarının kontrol edilmesi için bileşimler.
BR0015188A (pt) Composições farmacêuticas
MA29564B1 (fr) Formulation de 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
BR0107564A (pt) Composição de gliburida
PL348419A1 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
DK1408966T3 (da) Synergistiske farmaceutiske kombinationer til forebyggelse eller behandling af diabetes
TR200003156T2 (tr) Bir aktif içerik olarak izomalt içeren terapötik soğuk algınlığına karşı ajan.
BR9915692A (pt) Monohidrato de bromidrato de eletriptano
CO4970832A1 (es) Nuevas formulaciones y procesos para su fabricacion